Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Next Previous
Trial Profile

Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Troculeucel (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions
  • Acronyms ASK-AD
  • Sponsors NKGen Biotech

Most Recent Events

  • 22 Jul 2025 According to a NKGen Biotech media release, data from this trial will be presented at Alzheimers Association International Conference 2025 (AAIC 2025) to be held in Toronto, Canada and online from July 27-31, 2025.Paul Y. Song will be the presenter.
  • 13 Mar 2025 According to a NKGen Biotech media release, company announced that Paul Y. Song, M.D., Chairman &Chief Executive Officer of NKGen, will present Phase 1 clinical trial data, demonstrating early signs of clinical benefit, leading to the U.S. FDA Fast Track designation for moderate Alzheimers Disease and a new Investigational New Drug for Parkinsons Disease at the 13th Annual Alzheimers & Parkinsons Drug Development Summit to be held in Boston, MA, from March 18-20,2025.
  • 13 Feb 2025 According to a NKGen Biotech media release, final Results of the Phase 1 trial were previously disclosed at the Alzheimer Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top